The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …

The gut microbiome has been shown to influence the response of tumors to anti–PD-1
(programmed cell death–1) immunotherapy in preclinical mouse models and observational …

Background Immune checkpoint inhibitors are the standard of care for first-line treatment of
patients with metastatic renal cell carcinoma, yet optimised treatment of patients whose …

Background Patients with advanced melanoma have limited treatment options after
progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor …

Summary Background Anti-PD-1 therapy (hereafter referred to as anti-PD-1) induces long-
term disease control in approximately 30% of patients with metastatic melanoma; however …

Summary Background Previously, findings from CheckMate 238, a double-blind, phase 3
adjuvant trial in patients with resected stage IIIB–C or stage IV melanoma, showed …

Great advances in immune checkpoint blockade have resulted in a paradigm shift in patients
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …

Abstract PD-1/PD-L1 blockade therapy is a promising cancer treatment strategy, which has
revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 …

Cutaneous melanoma is the main cause of death for skin cancer. The majority of patients
with a diagnosis of melanoma have localized disease, which can be successfully treated …